Albendazole in the treatment of intestinal helminthiasis in children.
A single dose of 2% albendazole suspension (400 mg in 20 ml) was administered to 77 patients (42 males and 35 females), ages ranging between 2 to 12 years, with helminthic infections. Ascariasis was the most prevalent infection. Patients were followed-up for 3 weeks. The results showed that albendazole was highly effective against Ascaris lumbricoides, Ancylostoma duodenale and Enterobius vermicularis. Significant improvement was also observed in patients having infections due to Trichuris trichiura. Albendazole was well tolerated and did not produce any significant side-effects. Single dose albendazole appears to be appropriate for mass chemotherapy to control intestinal nematode infections in highly infected communities.
D015766:Albendazole; D000724:Ancylostomiasis / Q000188:drug therapy*; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D001196:Ascariasis / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D008297:Male; D010123:Oxyuriasis / Q000188:drug therapy*; D010270:Parasite Egg Count; D013997:Time Factors; D014257:Trichuriasis / Q000188:drug therapy*
D000871:Anthelmintics; D001562:Benzimidazoles; D015766:Albendazole